The relatively large molecular size, diastereoisomeric nature, and complex impurity profiles of therapeutic phosphorothioate oligonucleotides create significant analytical challenges for the quality control laboratory. To overcome the lack of selectivity inherent to traditional chromatographic approaches, an ion pair liquid chromatography-mass spectrometry (LCMS) method combining ultraviolet and mass spectrometry quantification was developed and validated for >35 different oligonucleotide drug substances and products, including several commercialized drugs. The selection of chromatographic and spectrometric conditions, data acquisition and processing, critical aspects of sample and buffer preparation and instrument maintenance, and results from method validation experiments are discussed.
Get full access to this article
View all access options for this article.
References
1.
CrookeST, VickersT, LimaW and WuH. (2008). Mechanisms of antisense drug action, an introduction. In: Antisense Drug Technology, Principles, Strategies, and Applications, 2nd edn. Crooke ST, ed. CRC Press, Boca Raton, pp. 3–46.
2.
Mipomersen (KYNAMRO TM) in 2013, Nusinersen (SPINRAZA TM) and Eteplirsen (EXONDYS 51 TM) in 2016, Patisiran (ONPATTRO TM) and Inotersen (TEGSEDI TM) in 2018, Volanesorsen (WAYLIVRA TM), Givosiran (GIVLAARI TM) and Golodirsen (Vyondys 53 TM) in 2019, Lumasiran (Oxlumo TM) and Inclisiran (Leqvio TM) in 2020, Casimersen (Amondys 45 TM) in 2021.
3.
Bennett CF. (2019). Therapeutic antisense oligonucleotides are coming of age. Annu Rev 783 Med, 70:307–321.
4.
SpringerAD and DowdySF. (2018). GalNAc-siRNA conjugats: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther, 28:109–118.
5.
PrakashTP, GrahamMJ, YuJ, CartyR, LowA, ChappellA, SchmidtK, ZhaoC, AghajanM, et al. (2014). Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res, 42:8796–8807.
6.
BergotBJ and EganW. (1992). Separation of synthetic phosphorothioate oligodeoxynucleotides from their oxygenated (phosphodiester) defect species by strong-anion-exchange high-performance liquid chromatography. J Chromatogr, 599:35–42.
7.
ZoltewiczJA, ClarkDF, SharpelessTW and GraheG. (1970). Kinetics and mechanism of the acid-catalyzed hydrolysis of some purine nucleoside. J Am Chem Soc, 92:1741–1750.
8.
SeptakM. (1996). Kinetic studies on depurination and detritylation of CPG-bound intermediates during oligonucleotide synthesis. Nucleic Acids Res, 24:3053–3058.
9.
ChenD, YanZ, ColeDL and SrivatsaGS. (1999). Analysis of internal (n-1)mer deletion sequences in synthetic oligodeoxyribonucleotides by hybridization to an immobilized probe array. Nucleic Acids Res, 27:389–395.
10.
FearonKL, StultsJT, BergorBJ and ChristensenLM. (1995). Investigation of the ‘n-1’ impurity in phosphorothioate oligonucleotides synthesized by the solid-phase β-cyanoethyl phosphoramidite method using stepwise sulfurization. Nucleic Acids Res, 23:2754–2761.
11.
TemsamaniJ, KubertM and AgrawalS. (1995). Sequence identity of the n-1 product of a synthetic oligonucleotide. Nucleic Acids Res, 23:1841–1844.
12.
KrotzAH, KlopchinPG, WalkerKL, SrivatsaGS, ColeDL and RavikumarVT. (1997). On the formation of longmers in phosphorothioate oligodeoxyribonucleotide synthesis. Tetrahedron Lett, 38:3875–3878.
13.
CapaldiDC, GausH, KrotzAH, ArnoldJ, CartyRL, MooreMN, ScozzariAN, LoweryK, ColeDL and RavikumarVT. (2003). Synthesis of high-quality antisense drugs. Addition of acrylonitrile to phosphorothioate oligonucleotides: adduct characterization and avoidance. Org Process Res Dev, 7:832–838.
14.
RentelC. (2007). Impurity profiling of phosphoramidites and oligonucleotides by LC-MS: integrated approach to quality control of oligonucleotide APIs. In: Poster Presentation at 9th Annual TIDES Conference, Las Vegas,NV.
15.
CalvittCJ, LevinDS, SheppardBT and GruenlohCJ. (2010). Chemistry at the 2′-position of constituent nucleotides controls degradation pathways of highly modified oligonucleotide molecules. Oligonucleotides, 20:239–251.
16.
CapaldiDC, TeasdaleA, HenryS, AkhtarN, den BestenC, Gao-SheridanS, KretschmerM, SharpeN, AndrewsB, BurmB and FoyJ. (2017). Impurities in oligonucleotide drug substances and drug products. Nucleic Acid Ther, 27:309–322.
17.
Capaldi DC. (2014). Detecting and controlling oligonucleotide impurities. In: Podium Presentation at 14th Annual EuroTides Conference, Berlin,Germany.
18.
CapaldiDC and ScozzariAN. (2008). Manufacturing and analytical processes for 2′-O-(2-methoxyethyl)-modified oligonucleotides. In: Antisense Drug Technology: Principles, Strategies and Applications, 2nd edn. Crooke ST, ed. CRC Press, Boca Raton, FL, pp. 401–434.
19.
SuzikiT, OhsumiS and MakinoK. (1994). Mechanistic studies on depurination and apurinic site chain breakage in oligodeoxynucleotides. Nucleic Acids Res, 22:4997–5003.
20.
GausHJ, OlsenP, Van SooyK, RentelC, TurneyB, WalkerKL, McArdleJV and CapaldiDC. (2005). Trichloroacetaldehyde modified oligonucleotides. Bioorg Med Chem Lett, 15:4118–4124.
21.
CapaldiDC, GausHJ, CartyRL, MooreMN, TurneyBJ, DecottigniesSD, McArdleJV, ScozzariAN, RavikumarVT and KrotzAH. (2004). Formation of 4,4′-dimethoxytrityl-C-phosphonate oligonucleotides. Bioorg Med Chem Lett, 14:4683–4690.
22.
Rentel CR. (2013). A control strategy for raw materials of oligonucleotide drug substances: application of ICH Q11. In: Podium Presentation at 15th Annual TIDES Conference, Boston,MA.
23.
MorganMA, KazakovSA and HechtSM. (1995). Phosphoryl migration during the chemical synthesis of RNA. Nucleic Acids Res, 23:3949–3953.
24.
RodriguezAA, CedilloI, MoweryBP, GausHJ, KrishnamoorthySS and McPhersonAK. (2014). Formation of the N2-acetyl-2,6-diaminopurine oligonucleotide impurity caused by acetyl capping. Bioorgan Med Chem Lett, 24:3243–3246.
25.
RodriguezAA, CedilloI and McPhersonAK. (2016). Conversion of adenine to 5-amino-4-pyrimidinylimidazole caused by acetyl capping during solid phase oligonucleotide synthesis. Bioorgan Med Chem Lett, 26:3468–3471.
26.
LorenzS, PrzybytekJ and SnobleK. (2009). Synthesis of oligonucleotides or phosphorothioate oligonucleotides with a capping reagent of N-methylimidazole free of 1, 3, 5-trimethylhexahydro-1, 3, 5-triazine. Patent WO2009052034, Honeywell International,Inc.
27.
BrooksJL, OlsenP, ChenL and RodriguezAA. (2017). UnyLinker dimer impurity characterization and process improvement. Tetrahedron Lett, 58:1050–1052.
28.
Hill KW. (2007). Understanding oligonucleotide production: identification of process-related impurities. In: Podium Presentation at DIA, 1st Oligonucleotide-Based Therapeutics Conference, Washington, DC.
29.
DuttaS, ChowdhuryG and GatesKS. (2007). Interstrand cross-links generated by abasic sites in duplex DNA. J Am Chem Soc, 129:1852–1853.
30.
KurataC, BradleyK, GausH, LuuN, CedilloI, RavikumarVT, Van SooyK, McArdleJV and CapaldiDC. (2006). Characterization of high molecular weight impurities in synthetic phosphorothioate oligonucleotides. Bioorg Med Chem Lett, 16:607–614.
31.
CramerH, FinnKJ and SinhaND. (2013). Oligonucleotide impurities and their origins. In: Analysis of Oligonucleotides and Their Related Substances. Okafo G, D Elder, M Webb, eds. ILM Publications, St Albans, pp. 21–100.
32.
Capaldi DC. (2006). Identification of impurities in oligonucleotide therapeutics. In: Podium Presentation at 6th Annual EuroTides Conference, Hamburg,Germany.
33.
El ZaharNM, MagdyN, El-KosasyAM and Bartlett.MG (2018). Chromatographic approaches for the characterization and quality control of therapeutic oligonucleotide impurities. Biomed Chrom, 32:e4088.
34.
LindahlT and NybergB. (1974). Heat induced deamination of cytidine residues in deoxyribonucleic acid. Biochemistry, 13:3405–3410.
35.
RentelC, DaCostaJ, RoussisS, ChanJ, CapaldiDC and MaiB. (2019). Determination of oligonucleotide deamination by high resolution mass spectrometry, J Pharm Biomed Anal, 173:56–61.
36.
Capaldi DC. (2011). Stress testing of oligonucleotides. In: Pharmaceutical Stress Testing, 2nd edn. Baertschi SW, KM Alsante, RA Reed, eds. Informa Healthcare, London, UK, pp. 391–425.
37.
RentelC, WangX, BattM, KurataC, OliverJ, GausHJ, KrotzAH, McArdleJV and CapaldiDC. (2005). Formation of modified cytosine residues in the presence of depurinated DNA. J Org Chem, 70:7841–7845.
38.
FlemingAM, MullerJG, DlouhyAC and BurrowsCJ. (2012). Structural context effects in the oxidation of 8-oxo-7,8-dihydro-2′-deoxyguanosine to hydantoin products: electrostatic, base stacking and base pairing. J Am Chem Soc, 134:15091–15102.
39.
SetlowRB and CarrierWL. (1966). Pyrimidine ÿimmers in ultraviolet-irradiated DNAs. J Mol Biol, 17:237–254.
40.
BonillaJV and SrivatsaGS, eds. (2011). Handbook of Analysis of Oligonucleotides and Related Products. CRC Press, Boca Raton,FL.
41.
OkafoG, ElderD and WebbM, eds. (2013). Analysis of Oligonucleotides and Their Related Substances. ILM Publications, Herts, United. Kingdom.
42.
GelfiC, PeregoM, MorelliS, NicolinA and RighettiPG. (1996). Analysis of antisense oligonucleotides by capillary electrophoresis, gel-slab electrophoresis, and HPLC: a comparison. Antisense Nucleic Acid Drug Dev, 6:47–53.
43.
CohenAS, VilenchikM, DudleyJL, GemborysMW and BourqueAJ. (1993). High-performance liquid chromatography and capillary gel electrophoresis as applied to antisense DNA. J Chromatogr A, 638:293–301.
44.
DeDionisioL. (1993). Capillary gel electrophoresis and the analysis of DNA phosphorothioates. J Chromatogr A, 652:101–108.
45.
MetelevV and AgrawalS. (1992). Ion-exchange high-performance liquid chromatography analysis of oligodeoxyribonucleotide phosphorothioates. Anal Biochem, 200:342–346.
46.
SrivatsaGS, KlopchinP, BattM, FeldmanM, CarlsonRH and ColeDL. (1997). Selectivity of anion exchange chromatography and capillary gel electrophoresis for the analysis of phosphorothioate oligonucleotides. J Pharm Biomed Anal, 16:619–630.
47.
HirschbeinBL and FearonKL. (1997). 31P NMR spectroscopy in oligonucleotide research and development. Antisense Nucleic Acid Drug Dev, 7:55–61.
48.
SmithM and BeckT. (2016). Quantitation of a low level coeluting impurity present in a modified oligonucleotide by both LC–MS and NMR. J Pharm Biomed Anal, 118:34–40.
49.
FountainKJ, GilarM and GeblerJC. (2003). Analysis of native and chemically modified oligonucleotides by tandem ion-pair reversed-phase high-performance liquid chromatography/electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom, 17:646–653.
50.
GilarM, FountainKJ, BudmanY, HolyokeL, DavoudiH and GeblerJC. (2003). Characterization of therapeutic oligonucleotides using liquid chromatography with on-line mass spectrometry detection. Oligonucleotides, 13:229–243.
51.
HuangZ, JayaseelanS, HebertJ, SeoH and NiuL. (2013). Single nucleotide resolution of RNAs up to 59 nucleotides by high-performance liquid chromatography. Anal Biochem, 435:35–43.
52.
GilarM, FountainKJ, BudmanY, NeueUD, YardleyKR, RainvillePD, RJ RussellII and GeblerJC. (2002). Ion-pair reversed-phase high-performance liquid chromatography analysis of oligonucleotides: retention prediction. J Chromatogr A, 958:167–182.
53.
McCarthySM, GilarM and GeblerJ. (2009). Reversed-phase ion-pair liquid chromatography analysis and purification of small interfering RNA. Anal Biochem, 390:181–188.
54.
CloseED, NwokeojiAO, MiltonD, CookK, HindochaDM, HookEC, WoodH and Dickman.MJ. Nucleic acid separations using superficially porous silica particles. J Chromatogr A, 1440:135–144.
55.
RoussisSG, PearceM and RentelC. (2019). Small alkyl amines as ion-pair reagents for the separation of positional isomers of impurities in phosphate diester oligonucleotides. J Chromatogr A, 1594:105–111.
56.
NollB, SeiffertS, VornlocherH-P and RoehlI. (2011). Characterization of small interfering RNA by non-denaturing ion-pair reversed-phase liquid chromatography. J Chromatogr A, 1218:5609–5617.
57.
GongL and McCullaghJSO. (2014). Comparing ion-pairing reagents and sample dissolution solvents for ion-pairing reversed-phase liquid chromatography electrospray ionization mass spectrometry analysis of oligonucleotides. Rapid Commun Mass Spectrom, 28:339–350.
58.
ApffelA, ChakelJA, FischerS, LichtenwalterK and HancockWS. (1997). Analysis of oligonucleotides by HPLC-electrospray ionization mass spectrometry. Anal Chem, 69:1320–1325.
59.
GilarM and NeueUD. (2007). Peak capacity in gradient reversed-phase liquid chromatography of biopolymers. Theoretical and practical implications for the separation of oligonucleotides. J Chromatogr A, 1169:139–150.
60.
GilarM. (2001). Analysis and purification of synthetic oligonucleotides by reversed-phase high-performance liquid chromatography with photodiode array and mass spectrometry detection. Anal Biochem, 298:196–206.
61.
ElzaharNM, MagdyN, El-KosasyAM and BartlettMG. (2018). Degradation product characterization of therapeutic oligonucleotides using liquid chromatography mass spectrometry. Anal Bioanal Chem, 410:3375–3384.
62.
McGinnisAC, GrubbEC and BartlettMG. (2013). Systematic optimization of ion-pairing agents and hexafluoroisopropanol for enhanced electrospray ionization mass spectrometry of oligonucleotides. Rapid Commun Mass Spectrom, 27:2655–2664.
63.
BasiriB, van HattumH, van DongenWD, MurphMM and BartlettMG. (2017). The role of fluorinated alcohols as mobile phase modifiers for LC-MS analysis of oligonucleotides. J Am Soc Mass Spectrom, 28:190–199.
64.
LevinDS, ShepperdBT and GruenlohCJ. (2011). Combining ion pairing agents for enhanced analysis of oligonucleotide therapeutics by reversed phase-ion pairing ultra performance liquid chromatography (UPLC). J Chromatogr A, 879:1587–1595.
65.
WuJ and McLuckeySA. (2004). Gas-phase fragmentation of oligonucleotide ions. Int J Mass Spectrometry, 237:197–241.
66.
WuL, WhiteDE, YeC, VogtFG, TerflothGJ and MatsuhashiH. (2012). Desulfurization of phosphorothioate oligonucleotides via the sulfur-by-oxygen replacement induced by the hydroxyl radical during negative electrospray ionization mass spectrometry. J Mass Spectrom, 47:836–844.
67.
GilarM, DeLanoM and Gritti.F (2021). Mitigation of analyte loss on metal surfaces in liquid chromatography. J Chromatogr A, 1650:462247.
68.
SchweikartF and HultheG. (2019). HPLC−UV−MS analysis: a source for severe oxidation artifacts. Anal Chem, 91:1748–1751.
69.
TangL and Kebarle.P (1993). Dependence of ion intensity in electrospray mass spectrometry on the concentration of the analytes in the electrosprayed solution. Anal Chem, 65:3654.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
